Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17. Operator: Good afternoon. My name is Karen, ...

State of New Jersey Common Pension Fund D grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.6 ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...